Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xarelto Rivaroxaban Atrial fibrillation, stroke prevention List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Thromboembolism (venous), prevention List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism Complete
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete
Xarelto Rivaroxaban Venous thromboembolic events, pulmonary embolism List with criteria/condition Complete
Xcopri cenobamate Epilepsy, partial-onset seizures Reimburse with clinical criteria and/or conditions Complete
Xeljanz tofacitinib Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Xeljanz tofacitinib Cancelled
Xeljanz Tofacitinib Arthritis, rheumatoid List with criteria/condition Complete